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Abstract
Background: The “PTEN hamartoma tumor syndrome” (PHTS) includes a group of syndromes caused by germline
mutations within the tumor suppressor gene “phosphatase and tensin homolog deleted on chromosome ten”
(PTEN), characterized by multiple polyps in the gastrointestinal tract and by a highly increased risk of developing
malignant tumours in many tissues.
The current work clarifies the molecular basis of PHTS in three unrelated Italian patients, and sheds light on
molecular pathway disregulation constitutively associated to PTEN alteration.
Methods: We performed a combination of RT-PCR, PCR, sequencing of the amplified fragments, Real Time PCR
and western blot techniques.
Results: Our data provide the first evidence of b-catenin accumulation in blood cells of patients with hereditary
cancer syndrome caused by germ-line PTEN alteration. In addition, for the first time we show, in all PHTS patients
analysed, alterations in the expression of TNFa, its receptors and IL-10. Importantly, the isoform of TNFRI that lacks
the DEATH domain (TNFRSF1b) was found to be overexpressed.
Conclusion: In light of our findings, we suggest that the PTEN pathway disregulation could determine, in non-
neoplastic cells of PHTS patients, cell survival and pro-inflammatory stimulation, mediated by the expression of
molecules such as b-catenin, TNFa and TNFa receptors, which could predispose these patients to the
development of multiple cancers.
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Background
PTEN hamartoma tumor syndrome is the term that has
recently been used to describe Cowden syndrome (CS),
Bannayan-Riley-Ruvalcaba syndrome (BRRS), Proteus syn-
drome (PS), and Proteus-like syndrome. These disorders
are all caused by mutations in the PTEN gene and are all
characterized by extraintestinal manifestations in addition
to intestinal polyposis. PHTS is inherited in an autosomal
dominant manner, and is likely to be underdiagnosed
because of its phenotypic variability, its incomplete
penetrance, and the fact that many of its component fea-
tures are subtle and occur in the general population [1].
CS is a rare multiple hamartoma syndrome with a
reported incidence of 1 in 200,000 individuals. This syn-
drome is characterized by macrocephaly, mucocutaneous
lesions (such as facial trichilemmoma), acral keratosis,
and glycogenic acanthosis of the esophagus and papillo-
matous papules. It is also associated with thyroid, breast,
and endometrial manifestations, including cancer in all of
these areas. Renal cancer has also been associated with
CS; the risk of developing gastrointestinal carcinoma in
CS is of about 13% [2]. The BRRS is a congenital disorder
characterized by macrocephaly, intestinal hamartomatous
polyposis, lipomas, and pigmentated macules of the glans
penis. It is recommended that individuals with BRRS
* Correspondence: marina.derosa@unina.it
† Contributed equally
1Dipartimento di Biochimica e Biotecnologie Mediche and CEINGE
Biotecnologie Avanzate, Università di Napoli Federico II, via S. Pansini 5,
Naples 80131, Italy
Full list of author information is available at the end of the article
Galatola et al. BMC Medical Genetics 2012, 13:28
http://www.biomedcentral.com/1471-2350/13/28
© 2012 Galatola et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.should be considered at risk for malignancy, as with CS.
PS is a complex, highly variable disorder involving conge-
nital malformations and hamartomatous overgrowth of
multiple tissues.
The diagnosis of PHTS is made only when a PTEN
mutation is identified. Approximately 85% of individuals
who meet the diagnostic criteria for CS and 65% of indivi-
duals with a clinical diagnosis of BRRS have a detectable
PTEN gene mutation. Since the most serious conse-
quences of PHTS relate to the increased risk of breast,
thyroid, endometrial, and renal cancers, the most impor-
tant aspect of managing individuals with a PTEN mutation
is increased cancer surveillance [3,4].
PTEN is a 9-exon tumour suppressor gene that encodes
for a 403 amino acid protein. It acts as a lipid phosphatase
to negatively regulate the PI3K/AKT/mTOR Pathway
[5,6]. Recently, nuclear compartmentalization of PTEN
has been found as a key component of its tumor-suppres-
sive activity [7]. Close to 100 different germ-line mutations
of PTEN have been reported to date encompassing point,
nonsense, frame shift, splice site, missense, and deletion/
insertion mutations. Most mutations occur in exon 5, but
mutations in all other exons, except the first, have also
been described. Around 10% of PTEN mutations occur in
the promoter region, and the role of epigenetic regulation
is not well understood.
Somatic PTEN mutations have been identified in a
l a r g en u m b e ro fs p o r a d i ct u m o u r ss u c ha sg l i o b l a s t o -
mas, prostate cancer, melanomas, thyroid and endome-
trial tumours [3].
Evidence exists indicating that PTEN is a functionally
haploinsufficient tumour suppressor gene [8]. Indeed, in
human cancers, monoallelic mutation of PTEN without
loss or mutation of the second allele is prevalent at an
early stage, whereas complete loss is observed at low fre-
quencies with the exception of advanced cancers [9,10].
Recent studies describe the functional relationship
between mRNAs produced by the PTEN tumour suppres-
sor gene and its pseudogene PTENP1, as well as the criti-
cal consequences of this interaction. These studies show
that PTENP1 is biologically active as it can regulates cellu-
lar levels of PTEN and plays a growth-suppressive role [8].
In the current work, we present data obtained by study-
ing three PHTS patients with a clinical diagnosis of CS
(PHTS2 and PHTS3) and BRRS (PHTS1), respectively.
The aim was to understand the pathogenetic mechanisms
of the PTEN tumour suppressor gene alteration, and to
clarify the molecular changes downstream of a PTEN
alteration and constitutively associated to it.
Methods
Patients
A total of 3 unrelated patients, exhibiting hamartomatous
polyposis, were referred by gastroenterologists to the
laboratory, for genetic analysis. The histological aspect of
the polyps was unambiguous in all cases and it is tipic of
PHTS polyps. Differential diagnosis with the juvenile
polyposis syndrome (JPS) was made for PHTS2 and
PHTS3 patients because none of the patients showed
polyps histologically characteristic of the JPS. In fact, in
both patients polyps were hamartomas with glandular
structures, muscle fibers and also ganglioneuromatosi
elements, while Juvenile polyps show a normal epithe-
lium with a dense stroma, an inflammatory infiltrate, and
a smooth surface with dilated, mucus-filled cystic glands
in the lamina propria. Muscle fibers and the proliferative
characteristics of adenomas are typically not seen in juve-
nile polyps [11]. In addition, the PHTS2 patient showed
extensive glycogenic acanthosis, that is a characteristic
feature of Cowden syndrome [12], whereas, the PHTS3
patient showed horseshoe kidney. It was the combination
of these elements that can be found in Cowden syndrome
to suggest the diagnosis. Clinical phenotype, family his-
tory and molecular characterization of each patient are
reported in Table 1.
Blood samples from healthy subjects were collected
from the same hospital as the PHTS patients.
Samples from all families that participated in the study
were collected after being granted authorization from the
“Comitato etico per le attività Biomediche - Carlo
Romano” of the University of Naples Federico II, with pro-
tocol number 120/10. Such authorization is given only
once the study has received ethical approval, and partici-
pants’ informed and written consent has been obtained.
Molecular analysis of the PTEN messenger
RT-PCR of PTEN full length coding region in PHTS patients
Cells from from 3 ml of peripheral blood of these three
PHTS patients were pelleted, total RNA was extracted
using Trizol reagent (invitrogen, Life Technologies, Ca,
USA), and cDNA was synthesized using 1 μgo ft o t a l
RNA, 500 ng of random hexamers and 1 μlS u p e r s c r i p t
III reverse transcriptase (INVITROGEN), in the pre-
sence of 4 μl 5X RT buffer, 1 μlD T T( 0 . 1M )a n d
1m Md N T P s .T h er e a c t i o nw a sr u nf o r5 0m i n sa t
42°C in a 20 μl reaction volume, heated to 70°C for
15 mins and quick chilled on ice. Next, 1 μlo ft h e
cDNA was amplified by PCR using the following couple
of oligonucleotides:
PTEN-5’UTR-1FP: TTCCATCCTGCAGAAGAAGC
[NM_000314.4]; start: +950;
PTEN-3’UTR-1RP: TCTGAGCATTCCCTCCATTC
[NM_000314.4]; start: + 2765.
The amplification reaction produced a fragment of
1 8 1 5b po fm o l e c u l a rw e i g h t .T h eP C Rp r o d u c t sw e r e
analysed on a 1% agarose gel in a trisacetic acid (TAE)-
EDTA standard buffer, and visualized by ethidium bro-
mide staining.
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Sequence analysis of the PTEN full length coding region
was performed on amplified fragments from the cDNA
of all three patients, using the following primer pairs:
PTEN-5’UTR2-FP: GCAGCTTCTGCCATCTCTCT;
[NM_000314.4]; start: +980;
PTEN-7cRP: TCACCACACACAGGTAACGG; [NM_
000314.4]; start: +1786;
PTEN 5cFP: TTGAAGACCATAACCCACCAC; [NM_
000314.4]; start: +1300;
PTEN-8cRP: CCTTGTCATTATCTGCACGC; [NM_
000314.4]; start: +1971;
PTEN-7cFP: CGACGGGAAGACAAGTTCAT;
[NM_000314.4]; start: +1728;
PTEN-3’UTR2-RP: TAAAACGGGAAAGTGCCATC;
[NM_000314.4]; start: +2530.
The analysis was performed in a 3100 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA). For nucleo-
tide numbering, the first A of the initiator ATG codon is
nucleotide +1 of the PTEN mRNA sequence [GenBank
Accession number NM_000314.4]. All oligonucleotides
were obtained with primer-BLAST Software http://www.
ncbi.nlm.nih.gov/tools/primer-blast/.
Real Time RT-PCR quantification analysis
Real Time PCR quantification analysis was performed for
the PTEN messenger. The relative expression was calcu-
lated with the comparative Ct method. Patient-number-
ing corresponds to that adopted in Table 1. Three ml of
peripheral blood cells from PHTS patients and healthy
subjects were pelleted after erythrocytes lysis and resus-
pended in a Trizol reagent. In order to better normalize
the healthy values, we used four blood mixes as controls,
each containing five samples collected from healthy sub-
jects, for a total of twenty controls (data not shown). In
order to allow accurate evaluation of interindividual
variability in expression, we also separately analysed 20
samples, collected from healty subjects. PHTS1, PHTS2
and PHTS3 are the three patients affected by PHTS syn-
drome, as reported in Table 1.
The PTEN mRNA quantification was carried out by
amplifying fragments spanning the junctions between
exons 5-6, compared to the glucuronidase transcript
fragment, using the following oligonucleotides:
PTEN-5c2FP: ATGGGGAAGTAAGGACCAGAG;
[NM_000314.4]; start: +1495;
PTEN-6cRP: TCTTGTGAAACAACAGTGCCA;
[NM_000314.4]; start: +1623.
The quantitative Real Time assays were performed using
the iCycler iQ Real Time Detection System (BIO-RAD).
Amplification was carried out within a total volume of 15
μl containing the SYBR Green PCR Master Mix 1X (BIO-
RAD), using 20 ng of cDNA. The Real Time PCR reaction
was optimized according to the manufacturer’si n s t r u c -
tions but scaled down to 15 μl per reaction. The PCR con-
ditions were standard and all reagents were contained in
the standard iQ™ SYBR Green Supermix (BIORAD). The
reaction protocol consisted in an initial predenaturation
step at 95°C for 3 mins followed by 40 two-step cycles at
95°C for 15 s and 60°C for 1 min.
At the end of the PCR, the temperature was increased
from 55 to 95°C at a rate of 3°C/min, and the fluorescence
was measured every 10 s to construct the melting curve.
A nontemplate control was run for each assay, and all
determinations were performed in triplicate to ensure
reproducibility. Synthesis of the expected PCR product
was confirmed by melting curve analysis. Oligonucleo-
tides yielding 100-150 bp-long PCR products at an
annealing temperature of 60°C were obtained with pri-
mer-BLAST Software http://www.ncbi.nlm.nih.gov/
tools/primer-blast/.
Molecolar analysis of PTEN gene and PTENP1 pseudogene
Genomic PCR and sequencing
Cells from 3 ml of peripheral blood of PHTS patients
and healty controls were pelleted and genomic DNA
was extracted using Nucleon BACC2 Kit (Amersham;
Biosciences)
Genomic PCR and sequencing of exon 5 was per-
formed for PHTS1 patient, using oligonucleotides com-
plementary to intronic neighboring boundary regions of
the exon
(PTENg5FP: TGTTAAGTTTGTATGCAACATTTCT;
[NC_ 000010.10] start: 89692673;
PTENg5RP: AACCCAAAATCTGTTTTCCA; [NC_
000010.10] start: 89693081), in order to distinguish the
gene sequence from the pseudogene sequence. The
Table 1 Clinical phenotype and molecular characterization of Italian PHTS patients studied
Patient S/
F
Age of
diagnosis
Mutation Clinical manifestations Affected relatives
PHTS1 F 53 yrs c.406
T®Cp .
C136R
BRRS: macrocephaly, brain asymmetry, arteriovenous malformations,
glycogenic acanthosis, hamartomatous gastric polyps, colon cancer,
penis macules, keratosis of the hands and feet
Father and one brother died of colon
cancer; they both showed penis
macules.
PHTS2 S 45 yrs ↓ mRNA CS: hamartomatous gastric Cowden polyps, colon cancer, glycogenic
acanthosis, keratosis of the hands and feet, a few freckles on penis
___
PHTS3 S 54 yrs ↓ mRNA CS: hamartomatous colonic Cowden polyps, colon cancer, horseshoe
kidney.
___
PHTS1, PHTS2 and PHTS3: patients affected by PHTS syndrome; F: familial cases; S: sporadic cases
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is: NC_000010.10.
Mutational analysis of PTEN promoter region, from
bp -1398 to bp +1, was performed by PCR and sequen-
cing. This region was amplified into two overlapping
fragments of 663 and 789 bp in molecular weight,
respectively, using the following primer pairs:
PTENp-FP: GTTTCTCGCCTCCTCTTCGT; [NC_
000010.10] start: 89623575;
PTENp-RP: ATGGCTGTCATGTCTGGGA; [NC_
000010.10] start: 89624237;
PTENp2-FP CTACACTGAGCAGCGTGGTC: [NC_
000010.10] start: 89622825;
PTENp2-RP GGCTGCACGGTTAGAAAAGA; [NC_
000010.10] start: 89623613.
Gene copy number quantification of PTEN gene and
PTENP1 pseudogene
For the genomic quantification of PTEN gene and
PTENP1 pseudogene, specific amplified fragments were
compared to a fragment of the exon 15 MUTYH gene.
For PTEN specific quantification, two short fragments,
one inside intron 9 and the other at the boundaries of
exon 5 and IVS5, were amplified, using the following
primer pairs:
PTEN-5c2FP: ATGGGGAAGTAAGGACCAGAG;
[NM_000314.4]; start: 1495;
PTENg5RP: AACCCAAAATCTGTTTTCCA; [NC_
000010.10] start: 89693081;
PTEN-IVS9-FP:AGGCCTCTTAAAGAT-
CATGTTTGT; [NC_ 000010.10] start: 89724893;
PTEN-IVS9-RP:AGAAAATTTAAAATGAAAACC-
CACA; [NC_ 000010.10] start: 89725035.
These oligonucleotides don’tr e c o g n i z et h ePTENP1
sequence, whereas for specific amplification of the 3’-
UTR of PTENP1, the primers described by Poliseno et
al. [8] were used. H1, H2 and H3 are three healthy sub-
jects supposedly not deleted for the target genes.
Molecular alterations of PI3K/akt and WNT pathways
associated to PHTS syndrome
Western blot assay of b-catenin protein
Total proteins were extracted from 3 ml of peripheral
blood cells (about 5-7 × 10
3/mL cells) using Trizol reagent
(invitrogen, Life Technologies, Ca, USA) following the
manufacturer’s instructions; concentrations were deter-
mined by using a protein assay kit adopting bovine serum
albumin standards, according to the manufacturer’s
instructions (Bio-Rad Laboratories, Hercules, CA, USA). A
total of 50 μg protein was separated by SDS-polyacrylamide
gel electrophoresis and blots were prepared on a nitrocellu-
lose membrane Amersham Hybond-ECL (Amersham, GE
healthcare, USA). The primary antibodies against b-catenin
(amino-terminal and phospho beta catenin-S552 antigen)
were from Cell Signaling technology (Beverly, MA, USA).
The antibody against actin was from Santa Cruz (Santa
Cruz, CA, USA). The membrane was probed with a sec-
ondary antibody against peroxidase-conjugated rabbit and
goat immunoglobulin G, and immunoreactive bands were
detected using the enhanced chemiluminescence HRP Sub-
strate Immobilon Western, Millipore (Millipore Corpora-
tion, Billerica, USA). H1-5,H 6-10,H 11-15,H 15-20 were mixes
of healthy subjects, performed as described before. PHTS1,
PHTS2 and PHTS3 were the patients affected by PHTS
syndrome, as reported in Table 1.
Real Time PCR quantification analysis of COX2, CCND1,
cMYC, and APC messengers
Relative expression was calculated with the comparative
Ct method and normalised against the Ct of Glucuroni-
dase (GUS) messenger. The quantitative RNA Real Time
assays were performed as described before. H1-5,H 6-10,
H11-15,H 15-20 were mixes of healthy subjects. Hm was the
mean value between all healthy samples used as calibrator
to measure the relative expression. PHTS1, PHTS2 and
PHTS3 were the three patients affected by PHTS syn-
drome, as reported in Table 1.
Cytokine disregulation on peripheral blood cells of PHTS
patients
Real Time PCR quantification analysis of IL10 and TNFa
mRNA
Messenger quantification was performed for IL10 and
TNFa and normalised against the Ct of Glucuronidase
(GUS) messenger. The assay was performed as described
before.
Western blot assay of TNFRI and TNFRII proteins
Primary antibodies against TNFRI and TNFRII were from
R&D System (R&D System, Minneapolis, USA). The anti-
body against actin was from Santa Cruz (Santa Cruz, CA,
USA). Secondary antibodies were against peroxidase-con-
jugated goat and mouse immunoglobulin G. The assay
was performed as described before.
H1-5,H 6-10,H 11-15,H 15-20 were mixes of healthy sub-
jects, performed as before. PHTS1, PHTS2 and PHTS3
were the three patients affected by PHTS syndrome, as
reported in Table 1.
RT-PCR and sequencing of TNFRIAb
Messenger expression of the beta isoform of TNFRIA
was analysed by RT-PCR and sequencing. One μlo ft h e
cDNA syntetized from RNA of each PHTS patient was
amplified using the following couple of oligonucleotides:
TNFRI-5cFP: AAACAGAACACCGTGTGCAC;
TNFRI-6BcRP: CTTGAATCTGGGAGGCAGAG.
Sequence analysis was performed using the same pri-
mer pairs, as previously described. The GeneBank acces-
sion number of TNFR1Ab is: EU927389.1.
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All statistical analyses were computed using Prism soft-
ware. The unpaired two-tailed t test with confident
intervals of 99% was calculated. A value of p< 0.005 was
considered statistically significant.
Results
Molecular analysis of the PTEN gene at DNA and RNA
level
We performed mutational analysis of the PTEN gene,
setting up a combination of RT-PCR reaction of the
whole cDNA, PCR of genomic region, including the pro-
moter region from bp -1398 to bp +1, sequencing of the
amplified fragments and Real Time PCR.
As shown in Table 1 patient PHTS1, affected by
BRRS, had a missense mutation named c.406T®Ci n
exon 5 of PTEN gene. This mutation, already described
in the literature, determines the aminoacidic change of a
cysteine residue at position 136 into an arginine [13,14].
The other two patients, PHTS2 and PHTS3 (both
affected by CS), showed a significant decrease in the
PTEN mRNA expression when analysed by Real Time
quantitative RT-PCR (Figure 1a) (unpaired two-tailed t
test, confident intervals 99% p: 0,0002); this statistic
result was the same when calculated with the twenty
healty controls separately and with the four mixes of
healty subject (data not shown). None of these patients
was a carrier of a PTEN point mutation of the promoter
or coding gene region, nor did they show intragenic or
whole gene deletion when analysed by Real Time geno-
mic PCR (Figure 1b). However, promoter iper-methyla-
tion cannot be excluded, and additional mechanisms
could be responsible for the PTEN down-expression in
these two patients. For example, point mutations in
gene regions not investigated, such as intronic regions
and regions at the 5’ and 3’ end of the gene (not
included in our analysis), or mutations in other genes
that could regulate PTEN expression, could be present
in these patients. Using the same technique, we also
performed a genomic quantification of the PTENP1
pseudogene, in light of its involvment in the PTEN mes-
senger regulation, the quantity of which still resulted
normal in all patients (Figure 1b) (unpaired two-tailed t
test, confident intervals 99%; pPTEN: 0,9161; pPTENP1:
0,7755).
Molecular alterations of PI3K/akt and WNT pathways are
observed in non-neoplastic cells of PHTS patients
To better clarify the patients’ molecular changes asso-
ciated to a germline PTEN alteration, we studied some
genes related to PTEN/PI3K/AKT molecular pathway or
WNT pathway, and typically involved in tumour develop-
ment. Indeed, a relatively large number of studies indi-
cate a cooperative effect of these two molecular pathways
[15]. It is already known that b-catenin phosphorylation
at Ser-552, promoted by PI3K-Akt signalling, is asso-
ciated with its stabilization, nuclear accumulation and
transcriptional activation. Furthermore, PI3K-Akt signal-
ling activation results in the inactivation of GSK-3b and
reduces N-terminal b-catenin phosphorylation, which is
associated with its degradation [16,17].
Thus, we performed a western blot analysis of b-cate-
nin on protein extracted from non-neoplastic peripheral
blood cells of PHTS patients and healthy subjects, to
verify whether PTEN alteration causes b-catenin intracel-
lular accumulation in these cells. As shown in Figure 2a,
b-catenin is detectable by using N-terminal antibody and
phospho-b-catenin (Ser552) only in PHTS patients; total
b-catenin (detected by N-terminal antibody) is absent in
all healthy controls analysed, while phospho-b-catenin
(Ser552) is detected mainly in PHTS patients and gives a
very faint signal in controls. The phospho-b-catenin
(Ser552) accumulation favors a model whereby de-regu-
lation of the PI3K/Akt signaling is responsabile for altera-
tion of the b-catenin expression, while total b-catenin
accumulation suggested a possible transcriptional activa-
tion of its target genes. In order to evaluate this hypoth-
esis, we performed Real Time RT-PCR experiments for
c-MYC, cycline D1 (CCND1)a n dCOX2 messenger, clas-
sically under the control of b-catenin transcription factor.
Following this, we also analysed the APC gene expres-
sion, as it is known to be the major regulator of the
WNT pathway. As expected, quantification of cMYC,
CCND1,a n dCOX2 messengers, conducted on RNA
extracted from peripheral blood cells of the three PHTS
patients and healthy subjects, revealed an mRNA overex-
pression of all these genes in the patients when compared
with the healthy subjects - with the exception of patient
PHTS3, who expresses a normal level of cMYC RNA
(Figure 2b) (unpaired two-tailed t test, confident intervals
99%: pcMYC = 0,0001; pCCND1 = 0,0001; pCOX2 = 0,0001).
As showed in Figure 2b, the APC transcript resulted
down-expressed only in patients PHTS2 and PHTS3
(affected by CS and carrier of PTEN mRNA down-
expression), again as compared with the healthy controls
(unpaired two-tailed t test, confident intervals 99%: pAPC
= 0,0001). The relative espression values of each tran-
script analysed, normalised versus the glucuronidase
(GUS) transcript, are reported in Figure 2b.
Cytokine dysregulation is observed in non-neoplastic cells
of PHTS patients
Finally, we performed Real Time mRNA quantification of
the IL10 and TNFa messengers and western blot analysis
of TNFARI and TNFARII. The relative quantification of
the IL-10 and TNFa mRNA revealed statistically signifi-
cant downregulation of IL-10 mRNA and upregulation of
TNFa mRNA in PHTS patients when compared with
Galatola et al. BMC Medical Genetics 2012, 13:28
http://www.biomedcentral.com/1471-2350/13/28
Page 5 of 10healthy controls (Figure 3a) (unpaired two-tailed t test,
confident intervals 99%: pIL-10 = 0,0001; pTNF = 0,0001).
As shown in Figure 3b, TNFARI and TNFRII proteins
were detectable mainly in the patients, in our experimental
conditions. Interestingly, the main western blot signal
obtained by using anti-TNFRI antibody in all three patients
highlights a protein of about 25 Kda that corresponds to
the isoform b of the TNFR1A, described by Wang et al.
[18]. This isoform, generated by an alternative splicing
mechanism and designated as TNFRSF1Ab [genomic
sequence GenBank accession number: EU927389; protein
sequence GenBank accession number: NP_001056], lacks
the trans-membrane helix and the full cytoplasmic region
including the DEATH domain compared to the full-length
protein, while retains the signal peptide and the conserved
binding domain, which corresponds to the TNFR (TNF
receptor) domain [18]. We have confirmed, by RT-PCR
and sequencing, that mRNA for this TNFRIA isoform was
expressed in our samples (Figure c and d).
Discussion
It is becoming increasingly evident that inflammation and
cancer are intricately related. Many cancers arise from
sites of infection, chronic irritation and inflammation
[19-21]. Two of the key molecules mediating the inflam-
matory processes in tumour promotion are cytokines
tumour necrosis factor-a (TNF-a), and IL10 [22-24].
Moreover, much data in the literature correlate TNFa
expression with PTEN gene expression [25-29]. Usually,
the TNFa induces apoptosis through TNFRI and func-
tions related to cell survival through TNFRII. The TNFa
binding to TNFRI activates apoptosis through two path-
ways, involving the adaptor proteins TNFRI-associated
death domain (TRADD), and Fas associated death
Figure 1 Alterations of PTEN gene in PHTS patients. a) Real Time PCR quantification analysis of PTEN mRNA. Real Time RT-PCR quantification
analysis was performed for the PTEN messenger. H1-20: mean value between all healthy samples used as calibrator to measure the relative
expression; H1,H 2, ... H20: healty subject supposedly not deleted for the target genes. The graph shows quantification of the PTEN mRNA of the
PHTS patients and twenty healty subjects. b) Copy number quantification of PTEN gene and PTENP1 pseudogene. Real Time PCR quantification
analysis was performed for PTEN and PTENP1 genomic sequences. IVS9: amplified fragment inside intron 9 of the PTEN gene; IVS5: amplified
fragment at the boundaries of exon 5 and IVS5 of the PTEN gene; PHTS1, PHTS2 and PHTS3: patients affected by PHTS syndrome, as reported in
Table 1. H1, H2 and H3: three healthy subjects supposedly not deleted for the target genes.
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the mobilization and nuclear entry of the transcription
factor nuclear factor-B( N F - B) [30,31]. However,
receptor crosstalk and overlapping functions are
described [31,32].
It is reasonable to hypothesize that the expression of
the isoform b of the TNFRIA observed in the PHTS
patients could represent a mechanism by which TNFRI,
lacking its DEATH domain, could shift from an apopto-
tic signal towards cell survival stimulation, thus inducing
tumour promotion. Additional experiments are neces-
sary to clarify the role that TNFRIAb could play in the
TNFa signalling.
The relationship between PI3K activation and the TNFa
pathway is controversial. Evidence exists that the PI3K-
Akt pathway negatively regulates NF-kB and the expres-
s i o no fi n f l a m m a t o r yg e n e s[ 3 3 , 3 4 ] ,a sw e l la st h a tP I 3 K
activation induces TNFa over-expression in different cell
types [35,36]. This last finding are in agreement with our
data. We cannot exclude that alterations of molecular
pathways, such as the IL10 and TNF pathways, showed in
non-neoplastc peripheral blood cells of PHTS patients are
related to specific roles that PTEN plays in the nucleus,
independent of the PI3K/Akt pathway [7].
These data represent the first evidence of b-catenin
accumulation in non-neoplastic cells of PHTS patients,
caused by germ-line PTEN alteration without a “second
hit” of gene inactivation taking place. In light of these
data, we suggest that b-catenin could represent a good
candidate as a diagnostic marker for hereditary colorec-
tal diseases that determine b-catenin accumulation. This
is mainly noteworthy for PHTS syndrome, which is
often underdiagnosed. An expansion of the current
study, to be conducted on a larger population, has been
planned. This should confirm the robustness of the data
presented herein.
Figure 2 Molecular alterations of PI3K/Akt and WNT pathways associated with PHTS syndrome. a) Western blot assay of b-catenin protein.
H1-5,H 6-10,H 11-15,H 15-20: mixes of healthy subjects. PHTS1, PHTS2 and PHTS3: patients affected by PHTS syndrome, as reported in Table 1. b) Real
Time PCR quantification analysis of COX2, CCND1, cMYC, and APC messengers. H1-5,H 6-10,H 11-15,H 15-20: mixes of healthy subjects; Hm: mean value
between all healthy samples used as calibrator to measure the relative expression; PHTS1, PHTS2 and PHTS3: patients affected by PHTS
syndrome, as reported in Table 1.
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dies. In human alveolar macrophages, bacterial lipopoly-
saccharide (LPS) exposure activates PI3-K/Akt,
inactivates GSK-3b, and causes accumulation of b-cate-
nin in the nucleus of any cell and expression of genes
that require nuclear
b-catenin for their activation [37]. In human endome-
trial cancer cells with PTEN mutation, the PI3K/Akt
survival pathway is involved in the regulation of COX-2
and PGE2 synthesis. The authors showed that Akt phos-
phorylation was high in mutated PTEN cells compared
to wild-type PTEN cells, and that this phosphorylation
Figure 3 Cytokine disregulation on peripheral blood cells of PHTS patientsa) Real Time PCR quantification analysis of IL10 and TNFa mRNA.
b) Western blot assay of TNFR1 and TNFR2.H 1-5,H 6-10,H 11-15,H 15-20: mixes of healthy subjects; Hm: mean value between all healthy samples used
as calibrator to measure the relative expression; PHTS1, PHTS2 and PHTS3: patients affected by PHTS syndrome, as reported in Table 1. c) RT-PCR
analysis of the TNFRSF1Ab isoform. S.M.: genomic molecular weight marker; B: amplified sample without cDNA template. d) sequence analysis of
the amplified fragments showed in Figure 3d. The genomic sequence GenBank accession number is: EU927389. The underlined nucleotide are
those showed in the electropherogram.
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mRNA, its protein levels, and prostaglandin E2 (PGE2)
production [38]. In colorectal cancer, PTEN knockdown
results in nuclear b-catenin accumulation and in
increased expression of downstream proteins c-MYC
and cycline D1 [28]. Moreover, Lee et al. demonstrated
that, during inflammatory bowel disease, PI3K/Akt sig-
nalling cooperates with Wnt to increase b-catenin sig-
nalling, determining the progression from chronic
ulcerative colitis to colitis-associated cancer [15].
In this scenario, the APC transcriptional down-regula-
tion we have observed in peripheral blood cells of two
PHTS patients, suggests an intrinsic cooperative action of
PI3K/Akt and Wnt signalling to increase b-catenin inta-
cellular concentration. Taking the latter into account,
and as previously described for other tumour suppressor
genes [39,40], PTEN mRNA molecular screening investi-
gations are necessary to obtain more precise molecular
diagnoses, with a view to better characterizing PHTS
patients and probably to explain the PHTS cases that
remain without identified molecular alterations. It is
interesting that the reduced APC levels are found in the
two cases that do not have a PTEN mutation identified
on DNA. We can not exclude that this could be due to
alternative mechanisms (possibly mutations in other
genes), that cause reduction in both APC and PTEN
mRNA level. Infact, though unlikely, the presence of
genomic rearrangements in PHTS2 and PHTS3, cannot
be completely ruled out with the methods used.
Conclusion
In conclusion, it is likely that PTEN germ-line alteration
and b-catenin accumulation, observed in peripheral
blood cells of PHTS patients, could determine a cell sur-
vival and pro-inflammatory stimulation mediated by the
expression of molecules such as COX2, CCND1 and
TNFa receptors. Increased levels of messengers cMYC
and CCND1 are often observed in different tumour
types, such as breast cancer, endometrial cancer, thyroid
cancer and ovarian cancer [41-43]. Interestingly, these
types of tumours correspond to the neoplasias most fre-
quently associated to PHTS syndrome. It is likely that
the overexpression of mRNA of cMYC and CCND1 in
non neoplastic cells of PHTS patients puts them at
hight risk of developing these types of tumours.
The data presented herein are in agreement with and
reinforces the results of Alimonti et al. [10], who pro-
pose a new “continuum model” for cancer initiation and
promotion for the PTEN tumour suppressor gene,
resulting from the subtle reduction in a tumour sup-
pressor gene without requiring an additional genetic hit
at that locus. In their model, tumours initiated by a
subtle downregulation of a tumour suppressor gene can
progress in the absence of LOH of the wild type allele
[10].
Knowledge of specific molecular pathways changes
downstream of PTEN alteration could be helpful in opti-
mizing molecular targeted therapy and preventative care,
not only for PHTS patients, but mainly because PTEN
mutations are involved in a wide range of human dis-
eases and cancers.
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